Raynaud's phenomenon and the possible use of foods

Journal of Food Science

Volumn 70, Issue 4, 2005, Pages

  Wright, Chris I ^a   Kroner, Christine I ^a   Draijer, Richard ^a  

^a UNILEVER RESEARCH VLAARDINGEN   (Netherlands)

Author keywords

Dietary intervention; Functional foods; Nutraceutical; Raynaud's; Vascular constriction

Indexed keywords

ALLIUM SATIVUM; GINKGO BILOBA; OENOTHERA; PRIMULA;

EID: 19444368798     PISSN: 00221147     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2621.2005.tb07196.x     Document Type: Short Survey

References (67)

1. Allen E, Brown G. 1932. Raynaud's disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 183:187-95.
2. Allen J, Frame JR, Murray A. 2002. Microvascular blood flow and skin temperature changes in the fingers following a deep inspiratory gasp. Physiol Measur 23:365-73.
3. Aylward M. 1979. Hexopal in Raynaud's disease. J Int Med Res 7:484-91.
4. Belch J. 1997. Raynaud's phenomenon. Cardiovasc Res 33:25-30.
5. Belch JJ, Ho M. 1996. Pharmacotherapy of Raynaud's phenomenon. Drugs 52:682-95.
6. Belch JJ, Shaw B, O'Dowd A, Saniabadi A, Leiberman P, Sturrock RD, Forbes CD. 1985. Evening primrose oil (Efamol) in treatment of Raynaud's phenomenon: a double blind study. Thrombosis Haemostasis 54:490-4.
7. Belch JJF, Capell HA, Cooke ED, Kirby JDT, Lau CS, Madhok R, Murphy E, Steinberg M. 1995. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheumatic Dis 54:197-200.
8. Belch JJF, Hill A. 2000. Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr 71:352S-6S.
9. Block JA, Sequeira W. 2001. Raynaud's phenomenon. Lancet 357:2042-8.
10. Boelsma E, Hendriks HFJ, Roza L. 2001. Nutritional skin care: health effects of micronutrients and fatty acids. Am J Clin Nutr 73:853-64.
11. Bongard O, Bounameaux H. 1993. Clinical investigation of skin microcirculation. Dermatology 186:6-11.
12. Bounameaux HM, Hellemans H, Verhaege R. 1986. Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl. Int Angiol 5:39-44.
13. Bruckner G, Webb P, Greenwell L, Richardson D. 1987. Fish oil increases peripheral capillary blood cell velocity in humans. Atherosclerosis 66:237-45.
14. Bunker CB, Reavley C, O'Shaughnessy DJ, Dowd PM. 1993. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. Lancet 342:80-2.
15. Cerinic MM, Generini S, Pignone A. 1997. New approaches to the treatment of Raynaud's phenomenon. Curr Opin Rheumatol 9:544-56.
16. Coffman J. 1989. Raynaud's phenomenon. New York: Oxford Univ. Press.
17. Cui J, Das DK, Bertelli A, Tosaki A. 2001. Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. Cardiovasc Res 254:227-34.
18. Daanen HAM. 2003. Finger cold-induced vasodilation: a review. Eur J Appl Physiol 89:411-26.
19. Darton K, Black CM. 1991. Pyroelectric vidicon thermography and cold challenge quantify the severity of Raynaud's phenomenon. Br J Rheumatol 30:190-5.
20. DiGiacomo RA, Kremer JM, Shah DM. 1989. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med 86:158-64.
21. Drossos GE, Toumpoulis IK, Katritsis DG, Ioannidis JP, Kontogiorgi P, Svarna E. 2003. Is vitamin C superior to diltiazem for radial artery vasodilation in patients awaiting coronary artery bypass grafting? J Thorac Cardiovasc Surg 125:330-5.
22. Freedman R, Mayes M. 1996. Familial aggregation of primary Raynaud's disease. Arthrit Rheumat 39:1189-91.
23. Gasser P. 1991. Reaction of capillary blood cell velocity in nailfold capillaries to nifedipine and ketanserin in patients with vasospastic disease. J Int Med Res 19:24-31.
24. Gasser P, Martina B, Dubler B. 1997. Reaction of capillary blood cell velocity in nailfold capillaries to L-carnitine in patients with vasospastic disease. Drugs Exp Clin Res 23:39-43.
25. Generini S, Del Rosso A, Pignone A, Cerinic MM. 2003. Current treatment options in Raynaud's phenomenon. Curr Treatment Options Cardiovasc Med 5:147-61.
26. Green MR, Ouderaa Fvd. 2003. Nutrigenetics: where next for the foods industry? Pharmacogenomics 3:191-3.
27. Hahn M, Heubach T, Steins A, Junger M. 1998. Hemodynamics in nailfold capillaries of patients with systemic scleroderma: synchronous measurements of capillary blood pressure and red blood cell velocity. J Invest Dermatol 110:982-5.
28. Herrick AL. 2003. Treatment of Raynaud's phenomenon: new insights and developments. Curr Rheumatol Rep 5:168-74.
29. Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K, Moore T, Braganza JM, Jayson MI. 2000. A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349-56.
30. Holti G. 1979. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. J Int Med Res 7:473-83.
31. Jung EM, Jung F, Mroietz C, Kiesewetter H, Pindur G, Wenzel E. 1991. Influence of garlic powder on cutaneous microcirculation. A randomised placebo-controlled double-blind study in apparently healthy subjects. Arzneimittelforschung 41:626-30.
32. Jung F, Jung EM, Mrowietz C, Kiesewetter H, Wenzel E. 1990a. Influence of garlic powder on cutaneous microcirculation: a randomised, placebo-controlled, double-blind, crossover study in apparently healthy subjects. Br J Clin Pract Suppl 69:30-5.
33. Jung F, Mrowietz C, Kiesewetter H, Wenzel E. 1990b. Effect of ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 40:589-93.
34. Kiesewetter H, Jung F, Mrowietz C, Wenzel E. 1992. Hemorrheological and circulatory effects of gincosan. Int J Clin Pharmacol Therap Toxicol 30:97-102.
35. Kiesewetter H, Jung F, Pindur G, Jung EM, Mrowietz C, Wenzel E. 1991. Effect of garlic on thrombocyte aggregation, microcirculation, and other risk factors. Int J Clin Pharmacol Therap Toxicol 29:151-5.
36. Kleijnen J, Knipschild P. 1992. Ginkgo biloba. Lancet 340:1136-9.
37. Költringer P, Eber O, Langsteger W, Wakonig P, Klima G, Rothlauer W. 1989. Mikrozirkulation und viskoelastizität des vollblutes unter ginkgo-biloba-extrakt. Perfusion 1:28-30.
38. Landry G, Edwards J, Porter J. 1996. Current management of Raynaud's syndrome. Adv Surg 30:333-47.
39. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W. 2001. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res 51:21-9.
40. Lau CS, McLaren M, Saniabadi A, Scott N, Belch JJF. 1991. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis - a preliminary study. Clin Exp Rheumatol 9:271-3.
41. Leppert J, Ringqvist A, Ahlner J, Myrdal U, Walker-Engström M, Wennmalm A, Ringqvist I. 1997. Seasonal variations in cyclic GMP response on whole-body cooling in women with primary Raynaud's phenomenon. Clin Sci 93:175-9.
42. LeRoy EC, Medsger TA. 1992. Raynaud's phenomenon: a propsal for classification. Clin Exp Rheumatol 10:485-8.
43. Mahoney B. 1999. Raynaud's syndrome. Podiatry encyclopedia [serial online]. Perth, Western Australia: School of Physiotherapy, Curtin Univ. of Technology Available from: www.podiatry.curtin.edu.au/encyclopedia/raynauds. Assessed Apr 22, 2005.
44. Malpas SC. 2004. What sets the long-term level of sympathetic nerve activity: is there a role for arterial baroreceptors? Am J Physiol 286:R1-R12.
45. Maricq H, Carpentier P, Weinrich M, Keil J, Palesch Y, Biro C, Vionnet-Fuasset M, Jiguet M, Valter I. 1997. Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison. J Rheumatol 24:879-89.
46. Mehlsen J, DrabæK H, Wiinberg N, Winther K. 2002. Effects of a ginkgo biloba extract on forearm hemodynamics in healthy volunteers. Clin Physiol Funct Imag 22:375-8.
47. Morris AC, Jacobs I, McLellan TM, Klugerman A, Wang LC, Zamecnik J. 1996. No ergogenic effect of ginseng ingestion. Int J Sports Nutr 6:263-71.
48. Muir AH, Robb R, McLaren M, Belch JJ. 2002. The use of ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vasc Med (Lond) 7:265-67.
49. Murai C, Sasaki T, Osaki T, Hatakeyama A, Shibata S, Yoshinaga K. 1989. Oral limaprost for Raynaud's phenomenon. Lancet 2:1218.
50. Purkayastha SS, Sharma RP, Ilavazhagan G, Sridharan K, Ranganathan S, Selvamurthy W. 1999. Effect of vitamin C and E in modulating peripheral vascular response to local cold stimulus in man at high altitude. Jpn J Physiol 49:159-67.
51. Raynaud AGM. 1888. On local asphyxia and symmetrical gangrene of the extremities. London: New Sydenham Society. 121 p.
52. Ring EF, Porto LO, Bacon PA. 1981. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome. J Int Med Res 9:393-400.
53. Ring EFJ, Bacon PA. 1977. Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena. J Int Med Res 5:217-22.
54. Root M, Anderson JJB. 2004. Dietary effects on nontraditional risk factors for heart disease. Nutr Res 24:827-38.
55. 1 analogue administration on peripheral skin temperature at high altitude. Angiology 45:455-60.
56. Shand B, Strey C, Scott R, Morrison Z, Gieseg S. 2003. Pilot study on the clinical effects of dietary supplementation with enzogenol®, a flavonoid extract of pine bark and vitamin C. Phytother Res 17:490-4.
57. Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C, Pignone A, Falcini F, Lotti T, Cagnoni M. 1999. Oxidative stress in systemic sclerosis. Molec Cell Biochem 196:85-91.
58. Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM. 2000. Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 155:1-15.
59. Sunderland GT, Belch JJ, Sturrock RD, Forbes CD, McKay AJ. 1988. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol 7:46-9.
60. Szallasi A, Di Marzo V. 2000. New perspectives on enigmatic vanilloid receptors. Trends Neurosci 23:491-7.
61. Tucker AT, Pearson RM, Cooke ED, Benjamin N. 1999. Effect of nitric-oxide generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial. Lancet 354:1670-5.
62. Turton EPL, Kent PJ, Kester RC. 1998. The etiology of Raynaud's phenomenon. Cardiovasc Surg 6:431-40.
63. Usuki K, Kanekura T, Aradono K, Kanzaki T. 1998. Effects of nicotine on peripheral cutaneous blood flow and skin temperature. J Dermatol Sci 16:173-81.
64. Vogler BK, Pittler MH, Ernst E. 1999. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol 55:567-75.
65. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. 1999. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 130:554-62.
66. Wohlrab J, Wohlrab D, Marsch WC. 2000. Acute effect of a dried ethanol-water extract of garlic on the microhaemovascular system in skin. Arzneimittelforschung 50: 606-612.
67. Yoshikawa T, Naito Y, Kondo M. 1999. Ginkgo biloba leaf extract: review of biological actions and clinical applications. Antioxidants Redox Signal 1:469-80.